Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Introductory Module
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Radiology Module
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
Program DescriptionRecently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing.
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Neurology Module
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis
Program DescriptionOver 80% of patients with multiple sclerosis (MS) experience related spasticity.
Category
Format
Credits
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Primary Care Module
Prog
Category
Format
Credits
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Attendance
Across the Spectrum: Transforming the Detection and Management of Disease State Transitions Across the Spectrum of Multiple Sclerosis
Program DescriptionMultiple sclerosis (MS) is a disease of transitions from subclinical changes to isolated events to definite MS. These clinical developments are often accompanied by changes in disease states ranging from active to inactive.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Inside Myasthenia Gravis: Where Providers and Patients Diverge on Defining Treatment Success
Program DescriptionThe understanding and prognosis of patients with myasthenia gravis (MG) have made dramatic leaps since the advent of serological evaluation and immunotherapy.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Deciphering Neuromyelitis Optica Spectrum Disorder: Addressing Real Clinician Questions Concerning Diagnosis and Management
OverviewThough neuromyelitis optica spectrum disorder (NMOSD) has had a specific lab marker (AQP4 antibody) for many years, its relapsing nature and overlapping syndromes still cause it to be confused with multiple conditions such as multiple sclerosis (MS), le
Category
Format
Credits
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Attendance

Pages